Showing results (41-50 of 324) with videos related to
Sort By:
Pageof 33
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]|October 1, 1978
Drug latentiation in cancer chemotherapyP Workman, J A DoubleBiochemical Pharmacology|October 1, 1982
Effects of the xanthine oxidase inhibitor allopurinol on the renal clearance of nitroimidazolesP Workman, R A WhiteCancer Chemotherapy and Pharmacology|January 1, 1988
When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?L S Freedman, P WorkmanThe Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in miceM I Walton, P WorkmanAnnals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1992
The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studiesM A Graham, P WorkmanBiochemical Pharmacology|June 1, 1990
Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxinM I Walton, P WorkmanBiochemical Pharmacology|January 15, 1986
Estimating the kinetic parameters for enzymatic drug metabolism in the whole animalJ V Watson, P WorkmanBritish Journal of Cancer|February 1, 1983
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazoleP R Twentyman, P WorkmanBritish Journal of Cancer|February 1, 1980
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogsR A White, P WorkmanBritish Journal of Cancer|May 1, 1983
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in miceF Y Lee, P WorkmanPageof 33